CNS Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNSP research report →
Companywww.cnspharma.com
CNS Pharmaceuticals, Inc. , a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme.
- CEO
- Rami Levin
- IPO
- 2019
- Employees
- 4
- HQ
- Houston, TX, US
Price Chart
Valuation
- Market Cap
- $2.93M
- P/E
- -0.21
- P/S
- 0.00
- P/B
- 48.77
- EV/EBITDA
- -0.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -238.69%
- ROIC
- -5485.47%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-15,850,564 · -6.68%
- EPS
- $-35.75 · 92.34%
- Op Income
- $-15,986,559
- FCF YoY
- 19.21%
Performance & Tape
- 52W High
- $15.73
- 52W Low
- $1.90
- 50D MA
- $3.34
- 200D MA
- $5.76
- Beta
- 0.54
- Avg Volume
- 1.45M
Get TickerSpark's AI analysis on CNSP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Charles Faith L. | buy | 7,100 |
| Mar 2, 26 | Faulkner Eric | other | 9,500 |
| Mar 2, 26 | Faulkner Eric | other | 0 |
| Mar 2, 26 | O'Loughlin Steve | other | 9,500 |
| Mar 2, 26 | O'Loughlin Steve | other | 0 |
| Jan 1, 26 | Levin Rami | other | 19,000 |
| Jan 1, 26 | Levin Rami | other | 0 |
| Nov 17, 25 | Keyes Jeffry R. | other | 1,517 |
| Nov 17, 25 | Cockroft Bettina M. | other | 1,517 |
| Nov 17, 25 | Climaco John M | other | 9,761 |
Our CNSP Coverage
We haven't published any research on CNSP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CNSP Report →